{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:10:34Z","timestamp":1793398234579,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.cmi.2024.02.023","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T12:21:34Z","timestamp":1709295694000},"page":"764-771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study"],"prefix":"10.1016","volume":"30","author":[{"given":"Aur\u00e9lie","family":"Jourdes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Cellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Escure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Jamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Danion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Sonntag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Soueges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Cazelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"de La Porte des Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lanternier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Brousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titouan","family":"Cazaubiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Collignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pieragostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Chaleteix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Redor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Cartau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Vallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2024.02.023_bib1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cmi.2024.02.023_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cmi.2024.02.023_bib3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cmi.2024.02.023_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.cmi.2024.02.023_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.17805","article-title":"The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies","volume":"196","author":"Swan","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2024.02.023_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.02.023_bib7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2024.02.023_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cmi.2024.02.023_bib9","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2024.02.023_bib10","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","article-title":"Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2024.02.023_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2024.02.023_bib12","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.cmi.2024.02.023_bib13","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.02.023_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2024.02.023_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/infdis\/161.3.397","article-title":"The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel","volume":"161","year":"1990","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2024.02.023_bib16","series-title":"Common terminology criteria for adverse events v5.0","year":"2017"},{"key":"10.1016\/j.cmi.2024.02.023_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2024.02.023_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41597-022-01720-9","article-title":"Toward practical transparent verifiable and long-term reproducible research using Guix","volume":"9","author":"Vallet","year":"2022","journal-title":"Sci Data"},{"key":"10.1016\/j.cmi.2024.02.023_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10245330310001652437","article-title":"Th1\/Th2 cells in patients with multiple myeloma","volume":"9","author":"Murakami","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.cmi.2024.02.023_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cmi.2024.02.023_bib21","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study","volume":"98","author":"Contejean","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cmi.2024.02.023_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2024.02.023_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.cmi.2024.02.023_bib24","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2024.02.023_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the advisory committee on immunization practices -","volume":"71","author":"Anderson","year":"2022","journal-title":"United States, 2022. MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2024.02.023_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices \u2013 United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cmi.2024.02.023_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and\u00a0risks of infections in patients with multiple myeloma managed with new\u00a0generation therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cmi.2024.02.023_bib28","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2024.02.023_bib29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis","volume":"122","author":"Schuster","year":"2020","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2024.02.023_bib30","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24000983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X24000983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T16:44:23Z","timestamp":1716655463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X24000983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1198743X24000983"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2024.02.023","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2024.02.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}